GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Cyclically Adjusted PB Ratio

Agenus (Agenus) Cyclically Adjusted PB Ratio : (As of May. 27, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Agenus Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agenus Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Agenus's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Cyclically Adjusted PB Ratio Chart

Agenus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agenus Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agenus's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Agenus's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agenus's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agenus's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Agenus's Cyclically Adjusted PB Ratio falls into.



Agenus Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Agenus's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Agenus's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-9.595/131.7762*131.7762
=-9.595

Current CPI (Mar. 2024) = 131.7762.

Agenus Quarterly Data

Book Value per Share CPI Adj_Book
201406 18.398 100.560 24.109
201409 15.592 100.428 20.459
201412 7.340 99.070 9.763
201503 13.061 99.621 17.277
201506 20.696 100.684 27.087
201509 18.188 100.392 23.874
201512 16.374 99.792 21.622
201603 10.275 100.470 13.477
201606 3.884 101.688 5.033
201609 -4.830 101.861 -6.249
201612 -8.913 101.863 -11.530
201703 1.804 102.862 2.311
201706 -3.510 103.349 -4.475
201709 -10.345 104.136 -13.091
201712 -14.909 104.011 -18.889
201803 -21.957 105.290 -27.481
201806 -20.271 106.317 -25.125
201809 -22.037 106.507 -27.265
201812 -28.745 105.998 -35.736
201903 -17.307 107.251 -21.265
201906 -22.910 108.070 -27.936
201909 -29.076 108.329 -35.369
201912 -32.703 108.420 -39.748
202003 -23.995 108.902 -29.035
202006 -25.508 108.767 -30.904
202009 -20.987 109.815 -25.184
202012 -20.773 109.897 -24.909
202103 -17.411 111.754 -20.530
202106 -21.940 114.631 -25.221
202109 3.382 115.734 3.851
202112 2.681 117.630 3.003
202203 1.179 121.301 1.281
202206 0.242 125.017 0.255
202209 -1.382 125.227 -1.454
202212 -4.011 125.222 -4.221
202303 -3.427 127.348 -3.546
202306 -5.072 128.729 -5.192
202309 -6.771 129.860 -6.871
202312 -8.131 129.419 -8.279
202403 -9.595 131.776 -9.595

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agenus  (NAS:AGEN) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Agenus Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Agenus's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agenus (Agenus) Business Description

Industry
Traded in Other Exchanges
Address
3 Forbes Road, Lexington, MA, USA, 02421
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Executives
Ulf Wiinberg director
Steven J O'day officer: Chief Medical Officer 2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen officer: Chairman & CEO 3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin officer: VP Finance 3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss officer: Chief Legal Officer 139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch director 280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark director 5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp 10 percent owner 1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan officer: Chief Technology Officer 3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis officer: See Remarks 3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns officer: V.P. and General Counsel AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell officer: Chief Operating Officer 3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis director FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan director ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese director C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010